Johnson & Johnson has achieved a offer to get Momenta Prescribed drugs for $fifty two.50 per share or $six.5 billion in an all dollars offer, the firms said.
The valuation represents a 70% top quality to Momenta’s closing cost on August 18, 2020. The company’s inventory cost jumped additional than 69% in premarket buying and selling Wednesday. As of yesterday, Momenta’s inventory was up 56.two% 12 months to date.
The offer will give J&J’s Janssen unit entry to nipocalimab, an experimental therapy Momenta is acquiring to handle autoimmune disorders. Nipocalimab is becoming tested as a procedure for myasthenia gravis, a neuromuscular sickness.
“Programs this sort of as nipocalimab have the opportunity to improve the life of many individuals suffering from autoimmune and fetal maternal disorders,” Momenta main govt officer Craig Wheeler said in a statement. “This acquisition provides potent worth for our shareholders and makes sure a level of investment